Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This protocol is planned as a multicentric, national, open-label trial designed to evaluate,
first, optimal dose of Velcade® (Bortezomib) in combination with melphalan and prednisone.
After optimal dose is known, the second aim is evaluate safety and tolerance of V-MP plan, in
respond terms, in a cohort of 60 patients. Finally, the entire results will be compared with
those obtained from a series of 100 patients, all of them over 70 years old, diagnosed of
Multiple Myeloma belonging to the GEM protocol finished in May 2003
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
PETHEMA Foundation
Collaborators:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium Pharmaceuticals, Inc.